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Introducing foreign genetic material into human ceils is essential for the elucidation f the function of various human genes and has potential 
use in the treatment of human diseases.by gene therapy. Inthis tudy we demonstrate that a defective h rpes simplex virus type I vector, pHSVlac, 
can effectively transfer and express the Escherichia coli L.ac 2 gene in a variety of exponential and quiescent human cells. The human cells tested 
included representative c lls derived from cancer-prone patients that presumably have various DNA repair deficiencies. 
HSV-1 vector, defective; Host range; Gene therapy; DNA damage, potentially lethal; DNA repair 
1. INTRODUCTION 
A defective herpes simplex virus type 1 (HSV-1) vec- 
tor, pHSVlac, was recently developed which contains 
the E. coli Lac 2 gene under the control of the HSV-1 
Immediate Early 4/5 promoter ([l], see fig.1 for the 
structure of pHSVlac). This vector was developed to in- 
troduce genetic material into postmitotic human or ro- 
dent neurons to alter physiology and perform gene 
therapy on neuronal disorders [I]. For example, 
Parkinson’s disease might be treated by introducing the 
tyrosine hydroxylase gene into neurons in the striatum 
[2]. Although HSV-1 has a wide host range, infecting 
various mammalian and avian cell types [3], the host 
range of pHSVlac virus has yet to be established. The 
purposes of this study were to determine its ability to 
express ,&galactosidase in a variety of human cell types, 
and to examine its effectiveness in growing as well as 
quiescent cells. 
We have investigated the ability of pHSVlac virus to 
infect and express foreign DNA (i.e., the E. coli Lac 2 
gene) in a variety of human normal and neoplastic cells 
(including fibroblasts, carcinomas and melanomas) and 
in human cancer-prone cells (i.e., cells from patients 
with Fanconi’s anemia, Bloom’s syndrome, ataxia 
telangiectasia and xeroderma pigmentosum variant). 
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The isolation and functional elucidation of human 
genes involved in DNA repair (particularly in DNA 
repair processes occurring in quiescent human cells) has 
been hampered by the inability of existing gene transfer 
methodologies to efficiently transfect human cells 
thought to be deficient in DNA repair, namely certain 
cells from cancer-prone patients ]4,5]. New means of 
introducing foreign DNA into these cells are essential 
to understand the role(s) of genes involved in DNA 
repair, and the role of DNA d~age-inducible genes or 
gene products which have recently been described 
16-81. 
2. MATERIALS AND METHODS 
2.1. Cell culture technique and viral inf~tio~ 
Cell designations used in this study are given in table 1; the celfs 
were obtained and characterized previously l&9]. The properties of 
specific cancer-prone diseases have been reviewed [4]; characteristics 
of individual cell types can be obtained from the Human Genetic Mu- 
tant Cell Repository 1988/1989 Catalog of Cell Lines (NIH Publica- 
tion No.@-2011, Oct., 1988). The growth state of W-Mel and 
AT2052 cells was monitored by assessing the percentage of [‘HIthy- 
midine-labeled nuclei at exponential and pIateau-phase under 
previously decsdribed conditions [6]. All cells were routinely deter- 
mined to be free of mycoplasma s described [lo]. 
Typical experiments were initiated by plating 5 x 104 viable cells in 
35 mm tissue culture dishes, or 1 x lo4 viable cells in 24 well tissue 
culture plates with a-media containing 10% fetal bovine serum, 
4 mM glutamine and nonessential amino acids [6]. A correction was 
made in the number of cells plated for each cell type based upon 
variations in plating efficiencies (table 1). Cells were grown in a 
humidified 6% COZ-94% air atmosphere at 37°C for 24 h. Medium 
was removed and triplicate cell cultures were infected with pHSVlac 
virus (grown with HSV-1 strain 17 ts K as helper virus [ll]), or with 
ts K alone, as described [l]. Infections were performed at a multiplici- 
ty of infection (m.0.i.) of 0.05 (unless otherwise indicated) in order 
to achieve a theoretical infection of 5%. ts K was titered using CV-1 
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Table 1 
Expression of ,&galactosidase derived from pHSVlac virus in human cancer-prone, normal and 
tumor cells 
Cell typea Percentage (olo) of fl-galactosidase-positive c lls 
Experiment 1 Experiment 2 
pHSVlac ts K pHSVlac ts K 
virus virus virus virus 
I Human normal cells 
GM2936B 1.46 f 0.04 0.0 1.95 + 0.68 0.0 
GM2907A 1.68 f 0.03 0.0 3.14 r 0.22 0.0 
AG2603 2.36 + 0.13 0.0 N.D. 
II Human tumor cells 
HEp-2 1.09 * 0.01 0.0 1.13 rt: 0.18 0.0 
HTB-152 2.10 f 0.41 0.0 2.62 t- 0.84 0.0 
Ul-Mel 
Exponential 5.84 f: 0.85 0.15 i 0.003 4.83 f 0.12 0.08 zr 0.001 
Plateau-phaseb 9.26 f 0.03 1.35 f 0.06 7.46 + 0.31 0.96 f 0.002 
III Human cancer-prone cells 
AT2052 
Exponential 1.12 -r: 0.16 0.0 1.95 tt 0.68 0.0 
Plateau-phaseb 9.61 f 0.15 0.0 N.D. 
BS2548 1.13 + 0.10 0:o N.D. 
FA2053 1.18 It 0.09 0.0 1.21 * 0.04 0.0 
XPV2359 1.82 f 0.03 0.0 2.11 f 0.12 0.0 
IV Monkey celis 
CVl 2.32 rfr 0.16 0.0 2.16 f 0.8 0.0 
a Cell designations are: GM2936B and GM2907A, normal nonfetal human fibroblasts; XPV2359 
(GM2359), xeroderma pigmentosum variant fibroblasts; AT2052 (GM2052), ataxia 
telangiectasia fibroblasts; BS2548 (GM2548A), Bloom’s syndrome fibroblasts; FA2053 
(GM2053), Fanconi’s anemia (Pancytopenia) fibroblasts; Ul-Mel, matignant human 
meianoma; HTB-152, metastatic human lung ~bros~~oma; HEp-2, human laryngeal 
epidermoid carcinoma; AG2603, normal fetal lung fibroblasts; and CVl, monkey kidney 
fibroblasts. Plating efficiencies were 70-90% for normal and tumor cells and 40-60% for 
human cancer-prone cells 
b Cells were infected in triplicate with an m.o.i. of 0.15 for Ul-Mel cells and 0.3 for AT2052 cells. 
Cell nuclei from plateau-phase cultures were stained with 1 pg/ml Hoechst dye 33258 
(Calbiochem-Behring Corp., La Jolla, CA) and counted using a UV-microscope to determine 
total cell numbers 
Cells were plated and infected at an m.o.i. of 0.05 (unless otherwise noted) as described in section 
2. Triplicate samples were scored in each experiment 
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celfs and pHSVlac was titered using PC12 cells. The titre of pHSVlac 
virus was 4 x 104 infectious particles/ml of pHSVIac and 5 x l@ pla- 
que forming units (i.e., pfu)/ml of ts K. The titre of ts K alone was 
1.0 x lo6 pfu/ml. Mock-infections were performed by adding an 
equivalent volume of cY-medium alone to parallel cultures. At 24 h 
after infection, cultures were fixed with 5% glutaraldehyde and 
scored for the percentage of cells expressing &galactosidase activity 
as described (l,ll-131. 
3. RESULTS 
To investigate the range of infectivity of pHSVlac 
virus, various human cancer-prone, normal and tumor 
cells were infected with pHSVlac virus and the number 
of ~-g~actosidase-positive c lls was determined. The 
results of two experiments, each completed in tripli- 
cate, are shown in table 1. All cell types, including 
representative cells from cancer-prone patients, showed 
160 
darkly stained cells representing positive ,&-gaiacto- 
sidase activity (fig.2) derived from the introduction of 
the E. co/i Lac 2 gene contained in pHSVlac (fig.1). 
Both exponential (i.e., > 35% [3H]thymidine-labeled 
nuclei) and plateau-phase arrested (~5% labeled 
nuclei) Ul-Mel or AT2052 cells showed @-galactosidase 
activity (table 1). pHSVlac virus was also able to ex- 
press fi-galactosidase activity in human neuroblastoma 
(SK-N-BE(2)) cells and in human glioma (Hs 683) cells 
derived from the temporal lobe (Geller, A., unpublish- 
ed results). None of the cultures infected with ts K 
alone or mock-infected contained fl-galactosidase-posi- 
tive cells, except for Ul-Mel cells (both plateau phase 
and log phase) which displayed a low number of lightly 
stained positive cells following infection with ts K alone 
(table 1). 
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HSV-1 
Fig.1. Structure of the defective HSV-1 vector, pHSVlac. The 
construction of the defective HSV-I vector, pHSVlac, has been 
previously described 111. pHSVlac contains a transcription unit 
composed of the HSV-1 IE 415 early promoter (arrow), the inter- 
vening sequence following that promoter (triangle), the E. co/i Luc 2 
gene and the SV-40 early region polyadenylation site. To be re- 
plicated during a HSV-1 viral infection and subsequently packaged 
into HSV-1 virus particles, pHSVlac contains an HSV-1 origin of 
DNA replication (circle) and an HSV-1 packaging site. pHSVlac also 
contains an ampicillin resistance (ampR) gene and an E. coli origin of 
DNA replication, which supports the growth of the pHSVlac vector 
in E. coli. Reprinted with permission from Science [l]. 
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Fig.3. &Galactosidase activity in W-Mel and AT2052 cells with 
increasing amounts of pHSVlac virus. Ul-Mel cells (6.0 x I@) or 
AT2052 cells (1.7 x IO’) were infected with S-80 ~1 of pHSVlac virus 
(corresponding to m.o.i.‘s of 0.01-0.40) in 24 well tissue culture 
plates. /3-Galactosidase-positive cells were visualized as described in 
section 2. 
AT2052 and Ul-Mel cells were chosen to investigate 
the efficiency of producing ,&galactosidase-positive 
cells following infection with increasing m.o.i of 
pHSVlac virus. Fig.3 shows a linear relationship bet- 
Fig.2. pHSVlac-mediated expression of fl-galactosidase activity in human normal, tumor and cancer-prone cells. Human cells were infected and 
scored for &galactosidase activity (appearing as darkly stained cells in photomicrographs A-H) as described in table 1 and section 2. Human 
cells shown are: (A) Ui-Mel (10 x); (B) Ul-Mel(32 x); (C) GM2936B (32 x ); (D) AG2603 (10 x ); (E) AT2052 (32 x); Q BS2548 (32 x); (G) 
FA2053 (32 x); and (H) XPV2359 (32 x). 
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ween increasing amounts of pHSVlac virus and the 
percentage of /3-galactosidase-positive Ul-Mel cells. 
More than 18% of Ul-Mel cells exhibited ,&galacto- 
sidase activity at a m.o.i. of 0.21. Under identical con- 
ditions, AT2052 cells showed a significantly lower, but 
linear production of P-galactosidase-positive cells; at 
an m.o.i. of 0.25 only 10% of the cells werefl-galacto- 
sidase-positive. No cell death was noted at any of 
m.o.i. of pHSVlac virus used. 
4. DISCUSSION 
Human cells of various types can be infected at a 
high efficiency (table 1) with foreign DNA carried by 
pHSVlac, a defective HSV-1 viral vector. pHSVlac 
virus infected exponential as well as quiescent human 
cells (table 1), and efficiently expressed its transcription 
unit (i.e., the E. coli Lac Z gene under the control of 
the HSV-1 Immediate Early 4/5 promoter) in epithelial 
(i.e., HEp-2), fibroblast (e.g., ataxia telangiectasia) 
and neural crest derivative (i.e., Ul-Mel melanoma) 
human cells. Stable expression, for up to 7 days, was 
observed in various quiescent normal, tumor and 
cancer-prone human cells (data not shown) and for up 
to two weeks in postmitotic rat neurons [l]. We have 
been unable, however, to obtain a significant frequency 
of exponential human cells which stably (for >6 cell 
divisions) express &galactosidase using pHSVlac (data 
not shown). The insertion of a selectable marker (e.g., 
neomycin-resistance) into pHSVlac may allow us to 
establish stable transfectants of mitotic cells. 
The ability of pHSVlac virus to deliver genes into 
human cells has the potential to both study and treat 
human diseases. New and improved modes of gene 
transfer are needed for the elucidation of the role(s) of 
various induced [6-81 and/or constitutive genes involv- 
ed in processes uch as DNA repair, which is carried 
out in quiescent human cells. This vector may be useful 
for the elucidation of genes involved in potentially 
lethal DNA damage repair (PLDR) following X- 
irradiation [6]. At present, cancer-prone cells represent 
the only potentially DNA repair-deficient human cells, 
and their resistance to transfection has hindered pro- 
gress in isolating and characterizing such human DNA 
repair genes [3-51. We have demonstrated that 
pHSVlac can efficiently transfer and express foreign 
DNA into these cells (table 1, figs 2 and 3). Because of 
the high infection frequencies (table 1) and large inser- 
tion capacity, HSV-1 vectors may provide a useful tool 
for elucidating human gene(s) involved in repairing 
various types of DNA damage. 
HSV-1 vectors carrying genes other than Lac Z may 
also be used in human gene therapy to treat neuronal 
diseases. For example, with such vectors one may be 
able to deliver the tyrosine hydroxylase gene into ap- 
propriate neurons in the brain to increase dopamine 
production to treat Parkinson’s disease [2]. 
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